M. Kuriyan

Learn More
A platelet apheresis product or single donor platelet (SDP) with a white blood cell content of 5 x 10(6) or below is considered optimal for transfusion. We modified the COBE spectra platelet collection protocol as follows: increased AC infusion rate of 1.1 ml/min/LTBV, setting the inlet: AC ratio configuration at high, and maintained the inlet flow rate of(More)
This article reviews transfusion risks with particular emphasis on the critically ill. It describes the various types of noninfectious,infectious, and mild-to-severe reactions that can occur in a trans-fused patient. The article describes differential diagnosis of these reactions and the handling and treatment of the patient. Diagnosis of the type of(More)
PURPOSE Vaccines, cytokines, and other biologic-based therapies are being developed as antineoplastic agents. Many of these agents are designed to induce an autologous immune response directed against the malignancy. In contrast, hematopoietic stem-cell transplantation is being developed as a form of allogeneic immunotherapy. This study tests the tolerance(More)
BACKGROUND ABO autoantibodies are rare. Most reported examples have been antibodies with 4 degrees C titers not greater than 256 in patients without apparent hemolytic anemia. Most high-titer, high-thermal-amplitude, complement-activating cold agglutinins are associated with hemolytic anemia. STUDY DESIGN AND METHODS A 52-year-old man presented with(More)
At present, healthy potential blood donors older than the age of 66 years often leave the donor pool for reasons of age alone, despite the fact that this demographic group is growing, is a potentially willing source of blood products, and constitutes the cohort with highest per capita use of blood and its derivatives. There is no clinical or physiological(More)
Allogeneic hematopoietic stem cell transplantation provides curative therapy for some patients with advanced hematologic malignancies. Disease response after allogeneic transplant is, at least in part, mediated by donor immune cells. In this report we describe a cellular therapy using haploidentical peripheral blood stem cells administered after very low(More)
In 1986, the American Red Cross/New Jersey Blood Service (NJBS) conducted a blood utilization review of the use of red blood cells (RBCs), platelets, and fresh frozen plasma (FFP) in nine hospitals in the NJBS region. The director of NJBS analyzed the collected data and categorized the justification criteria for blood transfusion. Their study found that(More)
Blood usage review is an essential aspect of hospital quality assurance. As part of a system for reviewing transfusion practices, the American Red Cross/New Jersey Blood Services has developed a series of microcomputer programs called the Blood Component Transfusion Audit. The programs use transfusion data collected on a standardized form to produce reports(More)